Soluble cytokine biomarkers are the master regulators of cell-to-cell communication-- the means by which one cell tells another what to do or where to go. Determining the biomarker signatures of immune cell populations reveals essential insights into cellular functions, for example, when probing new immuno-oncology targets or investigating treatment responses in patients.
This webcast will illustrate how biopharma researchers are using the multiplex Luminex® platform in a high-throughput manner to accelerate immuno-oncology discovery research from target discovery through preclinical development. A focus will be on novel soluble checkpoint panels, the integration of biomarker data with other analytics platforms, and strategies to handle large multiplex datasets from dozens of different programs.
For Research Use Only. Not For Use In Diagnostic Procedures.
Jennifer Koenitzer, Ph.D.
Bristol Myers Squibb
Principal Scientist, Clinical Mechanisms
Dr. Koenitzer is an immunologist by training and has been working in the Bristol Myers Squibb R&D department in Princeton, NJ since 2016. During her time at BMS she has focused on small molecule and biologics drug discovery in the immuno-oncology space; particularly in the area of T-cell checkpoint inhibitors and myeloid cell mediated immune suppression. One of her current job responsibilities is overseeing the biomarker profiling team, which provides high-throughput sample testing—using Luminex® multiplex assays—among other formats—to the entire BMS research community.
Yan Nikhamin, MS, MBA
Immunoassay Platform Specialist
Yan Nikhamin is an immunoassay specialist at Merck, based in New York. He is trained in Cell and Molecular Biology and has worked in developing CAR-T cells. Yan has been with Merck for 9 years helping our customers by sharing his experience.
Presented:Tue, April 28, 2020